Intelligent Bio Solutions Partners with Spjotgard for Scandinavian Drug Screening Market.
PorAinvest
miércoles, 25 de junio de 2025, 8:39 am ET2 min de lectura
INBS--
Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly expanded its presence in the region, positioning INBS' fingerprint drug testing technology as its primary solution. The company's Drug Screening System, which delivers results in under 10 minutes using fingerprint sweat, has gained traction across 450 accounts in 24 countries. The technology is being adopted across various sectors including logistics, construction, warehousing, education, and criminal justice [1].
The partnership between INBS and Spjotgard demonstrates a strategic go-to-market approach that leverages specialized regional distributors rather than building direct sales infrastructure in each territory. This capital-efficient strategy has enabled INBS to expand its global footprint to over 450 accounts across 24 countries. The technology's key competitive advantages—non-invasive collection method using fingerprint sweat, rapid results, elimination of observed sample collection, and comparable accuracy to traditional methods—are resonating strongly in the Scandinavian market [2].
Spjotgard's pharmaceutical expertise and regional connections are proving valuable for market development. Their strategic collaborations with providers of complementary services (drug-detection dogs, alcohol testing) create natural sales channels and reinforce INBS's technology as part of comprehensive substance testing solutions. The technology addresses specific regional needs, particularly in Sweden where concerns about drug driving and youth drug misuse are driving demand for more proactive testing approaches. The planned aggressive targeting of Norway indicates a structured geographic expansion strategy based on market readiness and regulatory environment [2].
INBS' Drug Screening System is primarily used for random testing, post-incident investigations, and for-cause testing scenarios. Customers appreciate its simplicity and reduced discomfort compared to traditional urine tests, which require invasive observation. INBS' Drug Screening System is used across logistics, construction, warehousing, education, and the criminal justice sector. In Sweden, growing concern about drug driving incidents and drug misuse among youth is leading organizations to explore more proactive testing strategies [1].
The partnership between INBS and Spjotgard shows strong Scandinavian adoption, extending INBS's global reach. The technology's success in the region is part of INBS's broader strategy to diversify revenue streams and reduce sector-specific risks. With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology, driving a global shift towards more progressive, dignified, and effective drug testing solutions.
References:
[1] https://www.globenewswire.com/news-release/2025/06/25/3105075/0/en/Intelligent-Bio-Solutions-and-Spjotgard-Drive-Rapid-Adoption-of-Fingerprint-Drug-Testing-Across-Scandinavia.html
[2] https://www.stocktitan.net/news/INBS/intelligent-bio-solutions-and-spjotgard-drive-rapid-adoption-of-vz6kcv9ey12d.html
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced the success of its partnership with Spjotgard, a distributor serving the Scandinavian market. The collaboration is accelerating the adoption of Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with growing interest in Finland. Spjotgard has developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as its flagship solution in response to rising demand for modern, dignified approaches to drug testing.
Intelligent Bio Solutions Inc. (Nasdaq: INBS), a medical technology company delivering intelligent, non-invasive drug screening solutions, has announced a successful partnership with Spjotgard, a distributor serving the Scandinavian market. The collaboration is accelerating the adoption of Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with growing interest in Finland. Spjotgard has developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as its flagship solution in response to rising demand for modern, dignified approaches to drug testing [1].Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly expanded its presence in the region, positioning INBS' fingerprint drug testing technology as its primary solution. The company's Drug Screening System, which delivers results in under 10 minutes using fingerprint sweat, has gained traction across 450 accounts in 24 countries. The technology is being adopted across various sectors including logistics, construction, warehousing, education, and criminal justice [1].
The partnership between INBS and Spjotgard demonstrates a strategic go-to-market approach that leverages specialized regional distributors rather than building direct sales infrastructure in each territory. This capital-efficient strategy has enabled INBS to expand its global footprint to over 450 accounts across 24 countries. The technology's key competitive advantages—non-invasive collection method using fingerprint sweat, rapid results, elimination of observed sample collection, and comparable accuracy to traditional methods—are resonating strongly in the Scandinavian market [2].
Spjotgard's pharmaceutical expertise and regional connections are proving valuable for market development. Their strategic collaborations with providers of complementary services (drug-detection dogs, alcohol testing) create natural sales channels and reinforce INBS's technology as part of comprehensive substance testing solutions. The technology addresses specific regional needs, particularly in Sweden where concerns about drug driving and youth drug misuse are driving demand for more proactive testing approaches. The planned aggressive targeting of Norway indicates a structured geographic expansion strategy based on market readiness and regulatory environment [2].
INBS' Drug Screening System is primarily used for random testing, post-incident investigations, and for-cause testing scenarios. Customers appreciate its simplicity and reduced discomfort compared to traditional urine tests, which require invasive observation. INBS' Drug Screening System is used across logistics, construction, warehousing, education, and the criminal justice sector. In Sweden, growing concern about drug driving incidents and drug misuse among youth is leading organizations to explore more proactive testing strategies [1].
The partnership between INBS and Spjotgard shows strong Scandinavian adoption, extending INBS's global reach. The technology's success in the region is part of INBS's broader strategy to diversify revenue streams and reduce sector-specific risks. With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology, driving a global shift towards more progressive, dignified, and effective drug testing solutions.
References:
[1] https://www.globenewswire.com/news-release/2025/06/25/3105075/0/en/Intelligent-Bio-Solutions-and-Spjotgard-Drive-Rapid-Adoption-of-Fingerprint-Drug-Testing-Across-Scandinavia.html
[2] https://www.stocktitan.net/news/INBS/intelligent-bio-solutions-and-spjotgard-drive-rapid-adoption-of-vz6kcv9ey12d.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios